{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:04:27Z","timestamp":1767830667656,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,8,4]],"date-time":"2018-08-04T00:00:00Z","timestamp":1533340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s10067-018-4221-0","type":"journal-article","created":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T23:39:19Z","timestamp":1533339559000},"page":"2381-2390","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study"],"prefix":"10.1007","volume":"37","author":[{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Durez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esperanza","family":"Naredo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikkel","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Meszaros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"De Leonardis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"de la Torre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"L\u00f3pez-Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Schlichting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Nantz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy","family":"Fleischmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,4]]},"reference":[{"key":"4221_CR1","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3899\/jrheum.121248","volume":"40","author":"M Broek van den","year":"2013","unstructured":"van den Broek M, Dirven L, Kroon HM, Kloppenburg M, Ronday HK, Peeters AJ, Kerstens PJ, Huizinga TW, Lems WF, Allaart CF (2013) Early local swelling and tenderness are associated with large-joint damage after 8 years of treatment to target in patients with recent-onset rheumatoid arthritis. J Rheumatol 40:624\u2013629","journal-title":"J Rheumatol"},{"key":"4221_CR2","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3389\/fimmu.2015.00384","volume":"6","author":"M Mellado","year":"2015","unstructured":"Mellado M, Mart\u00ednez-Mu\u00f1oz L, Cascio G et al (2015) T cell migration in rheumatoid arthritis. Front Immunol 6:384","journal-title":"Front Immunol"},{"key":"4221_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/ncprheum0020","volume":"1","author":"IB McInnes","year":"2005","unstructured":"McInnes IB, Liew FY (2005) Cytokine networks\u2014towards new therapies for rheumatoid arthritis. Nat Clin Pract Rheumatol 1:31\u201339","journal-title":"Nat Clin Pract Rheumatol"},{"key":"4221_CR4","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"IB McInnes","year":"2011","unstructured":"McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365:2205\u20132219","journal-title":"N Engl J Med"},{"key":"4221_CR5","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1093\/rheumatology\/ker192","volume":"50","author":"MG Bonilla-Hernan","year":"2011","unstructured":"Bonilla-Hernan MG, Miranda-Carus ME, Martin-Mola E (2011) New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors. Rheumatology 50:1542\u20131550","journal-title":"Rheumatology"},{"key":"4221_CR6","doi-asserted-by":"publisher","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","volume":"184","author":"JS Fridman","year":"2010","unstructured":"Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, Covington MB, Thomas B, Collier P, Favata MF, Wen X, Shi J, McGee R, Haley PJ, Shepard S, Rodgers JD, Yeleswaram S, Hollis G, Newton RC, Metcalf B, Friedman SM, Vaddi K (2010) Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 184:5298\u20135307","journal-title":"J Immunol"},{"key":"4221_CR7","unstructured":"Olumiant 2 mg and 4 mg film-coated tablets. SPC. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004085\/WC500223723.pdf\n                    \n                  . Accessed 11 April 2018"},{"key":"4221_CR8","unstructured":"Olumiant (baricitinib) tablets, for oral use. Prescribing information. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/207924s000lbl.pdf\n                    \n                   Accessed 21 June 2018"},{"key":"4221_CR9","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/art.39953","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, Zerbini CA, Gurbuz S, Dickson C, de Bono S, Schlichting D, Beattie S, Kuo WL, Rooney T, Macias W, Takeuchi T (2017) Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 69:506\u2013517","journal-title":"Arthritis Rheumatol"},{"key":"4221_CR10","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen ML, Reyes Gonzaga J, Yakushin S, Ishii T, Emoto K, Beattie S, Arora V, Gaich C, Rooney T, Schlichting D, Macias WL, de Bono S, Tanaka Y (2017) Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 376:652\u2013662","journal-title":"N Engl J Med"},{"key":"4221_CR11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","volume":"76","author":"M Dougados","year":"2017","unstructured":"Dougados M, van der Heijde D, Cehn YC, Greenwald M, Drescher E, Liu J, Beattie S, Witt S, de la Torre I, Gaich C, Rooney T, Schlichting D, de Bono S, Emery P (2017) Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 76:88\u201395","journal-title":"Ann Rheum Dis"},{"key":"4221_CR12","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, Beattie SD, Koch AE, Cardillo TE, Rooney TP, Macias WL, de Bono S, Schlichting DE, Smolen JS (2016) Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374:1243\u20131252","journal-title":"N Engl J Med"},{"key":"4221_CR13","first-page":"743","volume":"26","author":"D Heijde van der","year":"1999","unstructured":"van der Heijde D (1999) How to read radiographs according to the sharp\/van der Heijde method. J Rheumatol 26:743\u2013745","journal-title":"J Rheumatol"},{"key":"4221_CR14","first-page":"726","volume":"26","author":"D Heijde van der","year":"1999","unstructured":"van der Heijde D, Boers M, Lassere M (1999) Methodological issues in radiographic scoring methods in rheumatoid arthritis. J Rheumatol 26:726\u2013730","journal-title":"J Rheumatol"},{"key":"4221_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1136\/ard.2003.018457","volume":"64","author":"K Bruynesteyn","year":"2005","unstructured":"Bruynesteyn K, Boers M, Kostense P, van der Linden S, van der Heijde D (2005) Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Ann Rheum Dis 64:179\u2013182","journal-title":"Ann Rheum Dis"},{"key":"4221_CR16","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1136\/annrheumdis-2013-204920","volume":"74","author":"R Fleischmann","year":"2015","unstructured":"Fleischmann R, van der Heijde D, Koenig AS, Pedersen R, Szumski A, Marshall L, Bananis E (2015) How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index? Ann Rheum Dis 74:1132\u20131137","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4221_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000382","volume":"3","author":"RM Fleischmann","year":"2017","unstructured":"Fleischmann RM, van der Heijde D, Gardiner PV, Szumski A, Marshall L, Bananis E (2017) DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable. RMD Open 3(1):e000382","journal-title":"RMD Open"},{"key":"4221_CR18","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/acr.21649","volume":"64","author":"J Anderson","year":"2012","unstructured":"Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, Saag KG, O'dell JR, Kazi S (2012) Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 64:640\u2013647","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4221_CR19","first-page":"1","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL et al (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68:1\u201326","journal-title":"Arthritis Rheumatol"},{"key":"4221_CR20","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Po\u00f3r G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960\u2013977","journal-title":"Ann Rheum Dis"},{"key":"4221_CR21","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1002\/art.21235","volume":"52","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Ward MM, Machold KP, Nell VPK, Stamm T, Smolen JS (2005) Remission and active disease in rheumatoid arthritis. Arthritis Rheum 52:2625\u20132636","journal-title":"Arthritis Rheum"},{"key":"4221_CR22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1136\/annrheumdis-2011-201247","volume":"72","author":"A Kavanaugh","year":"2013","unstructured":"Kavanaugh A, Fleischmann RM, Emery P, Kupper H, Redden L, Guerette B, Santra S, Smolen JS (2013) Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 72:64\u201371","journal-title":"Ann Rheum Dis"},{"key":"4221_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","volume":"74","author":"P Emery","year":"2015","unstructured":"Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Barr\u00e9 E, Karyekar CS, Wong DA, Huizinga TWJ (2015) Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis 74:19\u201326","journal-title":"Ann Rheum Dis"},{"key":"4221_CR24","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1136\/annrheumdis-2013-204986","volume":"74","author":"K Hambardzumyan","year":"2015","unstructured":"Hambardzumyan K, Bolce R, Saevarsdottir S, Cruickshank SE, Sasso EH, Chernoff D, Forslind K, Petersson IF, Geborek P, van Vollenhoven RF (2015) Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. Ann Rheum Dis 74:1102\u20131109","journal-title":"Ann Rheum Dis"},{"key":"4221_CR25","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, Yamamoto K (2018) Rheumatoid arthritis. Nat Rev Dis Primers 4:18001","journal-title":"Nat Rev Dis Primers"},{"key":"4221_CR26","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1136\/ard.2008.088245","volume":"68","author":"ML Hetland","year":"2009","unstructured":"Hetland ML, Ejbjerg B, Horslev-Petersen K, Jacobsen S, Vestergaard A, Jurik AG, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS, Tarp U, Skjodt H, Pedersen JK, Majgaard O, Svendsen AJ, Ellingsen T, Lindegaard H, Christensen AF, Vallo J, Torfing T, Narvestad E, Thomsen HS, Ostergaard M, and the CIMESTRA study group (2009) MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis 68:384\u2013390","journal-title":"Ann Rheum Dis"},{"key":"4221_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/rheumatology\/keq230","volume":"50","author":"DP Rooy de","year":"2011","unstructured":"de Rooy DP, van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH (2011) Predicting arthritis outcomes\u2014what can be learned from the Leiden Early Arthritis Clinic? Rheumatology 50:93\u2013100","journal-title":"Rheumatology"},{"key":"4221_CR28","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1093\/rheumatology\/kew197","volume":"55","author":"DF McWilliams","year":"2016","unstructured":"McWilliams DF, Marshall M, Jayakumar K, Doherty S, Doherty M, Zhang W, Kiely PD, Young A, Walsh DA (2016) Erosive and osteoarthritic structural progression in early rheumatoid arthritis. Rheumatology 55:1477\u20131488","journal-title":"Rheumatology"},{"key":"4221_CR29","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/acr.23427","volume":"70","author":"B M\u00f6ller","year":"2017","unstructured":"M\u00f6ller B, Everts-Graber J, Florentinus S, Li Y, Kupper H, Finckh A (2017) Low hemoglobin predicts radiographic damage progression in early rheumatoid arthritis \u2013 secondary analysis from a phase III trial. Arthritis Care Res (Hoboken) 70:861\u2013868. \n                    https:\/\/doi.org\/10.1002\/acr.23427","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4221_CR30","doi-asserted-by":"crossref","unstructured":"Stojanovic S, Stamenkovic B, Stoimenov TJ, Nedovic J, Zivkovic V, Despotovic M, Pavlovic D (2017) Association of tumor necrosis factor-\u03b1 (G-308A) genetic variant with matrix metalloproteinase-9 activity and joint destruction in early rheumatoid arthritis. Clin Rheumatol 36:1479\u20131485","DOI":"10.1007\/s10067-017-3699-1"},{"key":"4221_CR31","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13075-017-1403-0","volume":"19","author":"M Ziegelasch","year":"2017","unstructured":"Ziegelasch M, Forslind K, Skogh T, Riklund K, Kastbom A, Berglin E (2017) Decrease in bone mineral density during 3 months after diagnosis of early rheumatoid arthritis measured by digital X-ray radiogrammetry predicts radiographic joint damage after one year. Arthritis Res Ther 19:195","journal-title":"Arthritis Res Ther"},{"key":"4221_CR32","first-page":"641","volume":"34","author":"J Asikainen","year":"2016","unstructured":"Asikainen J, Nikiphorou E, Kaarela K, Lindqvist E, H\u00e4kkinen A, Kautiainen H, Hannonen P, Rannio T, Sokka T (2016) Is long-term radiographic joint damage different between men and women? Prospective longitudinal data analysis of four early RA cohorts with greater than 15 years follow-up. Clin Exp Rheumatol 34:641\u2013645","journal-title":"Clin Exp Rheumatol"},{"key":"4221_CR33","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s00296-017-3845-8","volume":"37","author":"MA Quintana-Duque","year":"2017","unstructured":"Quintana-Duque MA, Rondon-Herrera F, Calvo-Paramo E, Yunis JJ, Varela-Nari\u00f1o A, Iglesias-Gamarra A (2017) The impact of smoking on disease activity, disability, and radiographic damage in rheumatoid arthritis: is cigarette protective? Rheumatol Int 37:2065\u20132070","journal-title":"Rheumatol Int"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4221-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4221-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4221-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T12:44:54Z","timestamp":1569156294000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4221-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,4]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["4221"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4221-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,4]]},"assertion":[{"value":"1 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RA-BEGIN was conducted in accordance with ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines, and was approved by each centre\u2019s institutional review board or ethics committee. All patients gave informed consent before participating in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Professor van der Heijde has received consulting fees from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi, Eli Lilly and Company, Galapagos, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, and UCB and is a Director of Imaging Rheumatology BV. Professor Durez has received speaker fees from Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, and Sanofi. Professor Schett has received speaker honoraria from AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, and Novartis. Esperanza Naredo has received speaker\/consultant fees from AbbVie, Roche, Bristol-Myers Squibb, Pfizer, UCB, Eli Lilly and Company, Novartis, Janssen, and Celgene. Mikkel \u00d8stergaard has received research support and\/or consultancy\/speaker fees from AbbVie, Bristol-Myers Squibb, Boehringer-Ingelheim, Celgene, Eli Lilly and Company, Centocor, GlaxoSmithKline, Hospira, Janssen, Merck, Mundipharma, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Takeda, UCB, and Wyeth. Gabriella Meszaros, Francesco De Leonardis, Inmaculada de la Torre, Pedro L\u00f3pez-Romero, Douglas Schlichting, and Eric Nantz are employees and shareholders of Eli Lilly and Company. Professor Fleischmann has received consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Eli Lilly and Company, Pfizer, and Sanofi-Aventis and research grants from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Janssen, Eli Lilly and Company, Merck, Pfizer, Regeneron, Roche, Sanofi-Aventis, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}